2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Ivonescimab: new trials by email Literature Review of Ivonescimab trials Research Report on Ivonescimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC AK112, AK112 + Neoadjuvant chemotherapy - Esophageal Squamous Cell Carcinoma, Ivonescimab | Phase 1 / Phase 2 | Recruiting | Tang-Du Hospital | 45 | 2026-01-28 | 2026-02-03 |
| Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma Ivonescimab - Ivonescimab, Clear Cell Renal Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-07-02 | 2026-08-20 |
Carcinoma, Renal Cell (1) · Esophageal Squamous Cell Carcinoma (1)
Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
M.D. Anderson Cancer Center (1) · Tang-Du Hospital (1)
China (1) · United States (1)